Document is current
Any future updates will be listed below
-
Authors
Steinsdörfer, Leonie
Zülch, Lilli
Schäfer, Anna
Frey, Benjamin
Corradini, Stefanie
Fietkau, Rainer
Gaipl, Udo S.
Jost, Tina https://orcid.org/0000-0001-8767-3774
-
Funding
Funding for this research was provided by:
Interdisciplinary Center for Clinical Research (IZKF) Erlangen
Universitätsklinikum Erlangen
- License Information
-
More Information
Article History
Received: 8 January 2026
Accepted: 17 March 2026
First Online: 17 April 2026
Declarations
:
: L. Steinsdörfer, L. Zülch, A. Schäfer, B. Frey, S. Corradini, R. Fietkau, U.S. Gaipl, and T. Jost declare that they have no competing interests.
: This assay involves blood withdrawals and the cultivation of human primary cells. All results presented in this manuscript are covered by the ethical approval of the IMMO-NHD trial, and written informed consent was obtained from all donors. Approval was granted by the institutional review board of Friedrich-Alexander-Universität Erlangen-Nürnberg on November 9, 2022 (application number 21-415-B). Blood cells were isolated from leukoreduction system chambers (LRSC) of healthy, anonymous donors having undergone a strict health check by the Transfusion Medicine and Hemostaseology Department of the Universitätsklinikum Erlangen (Germany). The permission to use this LRSC was given by the institutional review board at Friedrich-Alexander-Universität Erlangen-Nürnberg approved the study (no. 48_19 B; approved September 12, 2019). The study was performed in accordance with the Declaration of Helsinki. All patients gave written informed consent that comprised a data privacy clause for data collection and analysis for research purposes.
